Associations between purine metabolites and clinical symptoms in schizophrenia

Jeffrey K. Yao, Ruth Condray, George G. Dougherty, Matcheri S. Keshavan, Debra M. Montrose, Wayne R. Matson, Joseph Patrick McEvoy, Rima Kaddurah-Daouk, Ravinder D. Reddy

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background: The antioxidant defense system, which is known to be dysregulated in schizophrenia, is closely linked to the dynamics of purine pathway. Thus, alterations in the homeostatic balance in the purine pathway may be involved in the pathophysiology of schizophrenia. Methodology/Principal Findings: Breakdown products in purine pathway were measured using high-pressure liquid chromatography coupled with a coulometric multi-electrode array system for 25 first-episode neuroleptic-naïve patients with schizophrenia at baseline and at 4-weeks following initiation of treatment with antipsychotic medication. Associations between these metabolites and clinical and neurological symptoms were examined at both time points. The ratio of uric acid and guanine measured at baseline predicted clinical improvement following four weeks of treatment with antipsychotic medication. Baseline levels of purine metabolites also predicted clinical and neurological symtpoms recorded at baseline; level of guanosine was associated with degree of clinical thought disturbance, and the ratio of xanthosine to guanosine at baseline predicted degree of impairment in the repetition and sequencing of actions. Conclusions/Significance: Findings suggest an association between optimal levels of purine byproducts and dynamics in clinical symptoms and adjustment, as well as in the integrity of sensory and motor processing. Taken together, alterations in purine catabolism may have clinical relevance in schizophrenia pathology.

Original languageEnglish (US)
Article numbere42165
JournalPloS one
Volume7
Issue number8
DOIs
StatePublished - Aug 14 2012

Fingerprint

purines
Metabolites
signs and symptoms (animals and humans)
Schizophrenia
metabolites
Antipsychotic Agents
guanosine
Guanosine
drug therapy
High pressure liquid chromatography
Social Adjustment
guanine
Guanine
Pathology
uric acid
pathophysiology
Uric Acid
electrodes
byproducts
Byproducts

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Yao, J. K., Condray, R., Dougherty, G. G., Keshavan, M. S., Montrose, D. M., Matson, W. R., ... Reddy, R. D. (2012). Associations between purine metabolites and clinical symptoms in schizophrenia. PloS one, 7(8), [e42165]. https://doi.org/10.1371/journal.pone.0042165

Associations between purine metabolites and clinical symptoms in schizophrenia. / Yao, Jeffrey K.; Condray, Ruth; Dougherty, George G.; Keshavan, Matcheri S.; Montrose, Debra M.; Matson, Wayne R.; McEvoy, Joseph Patrick; Kaddurah-Daouk, Rima; Reddy, Ravinder D.

In: PloS one, Vol. 7, No. 8, e42165, 14.08.2012.

Research output: Contribution to journalArticle

Yao, JK, Condray, R, Dougherty, GG, Keshavan, MS, Montrose, DM, Matson, WR, McEvoy, JP, Kaddurah-Daouk, R & Reddy, RD 2012, 'Associations between purine metabolites and clinical symptoms in schizophrenia', PloS one, vol. 7, no. 8, e42165. https://doi.org/10.1371/journal.pone.0042165
Yao JK, Condray R, Dougherty GG, Keshavan MS, Montrose DM, Matson WR et al. Associations between purine metabolites and clinical symptoms in schizophrenia. PloS one. 2012 Aug 14;7(8). e42165. https://doi.org/10.1371/journal.pone.0042165
Yao, Jeffrey K. ; Condray, Ruth ; Dougherty, George G. ; Keshavan, Matcheri S. ; Montrose, Debra M. ; Matson, Wayne R. ; McEvoy, Joseph Patrick ; Kaddurah-Daouk, Rima ; Reddy, Ravinder D. / Associations between purine metabolites and clinical symptoms in schizophrenia. In: PloS one. 2012 ; Vol. 7, No. 8.
@article{2f1b2c26bab64f23933da6a97670d21b,
title = "Associations between purine metabolites and clinical symptoms in schizophrenia",
abstract = "Background: The antioxidant defense system, which is known to be dysregulated in schizophrenia, is closely linked to the dynamics of purine pathway. Thus, alterations in the homeostatic balance in the purine pathway may be involved in the pathophysiology of schizophrenia. Methodology/Principal Findings: Breakdown products in purine pathway were measured using high-pressure liquid chromatography coupled with a coulometric multi-electrode array system for 25 first-episode neuroleptic-na{\"i}ve patients with schizophrenia at baseline and at 4-weeks following initiation of treatment with antipsychotic medication. Associations between these metabolites and clinical and neurological symptoms were examined at both time points. The ratio of uric acid and guanine measured at baseline predicted clinical improvement following four weeks of treatment with antipsychotic medication. Baseline levels of purine metabolites also predicted clinical and neurological symtpoms recorded at baseline; level of guanosine was associated with degree of clinical thought disturbance, and the ratio of xanthosine to guanosine at baseline predicted degree of impairment in the repetition and sequencing of actions. Conclusions/Significance: Findings suggest an association between optimal levels of purine byproducts and dynamics in clinical symptoms and adjustment, as well as in the integrity of sensory and motor processing. Taken together, alterations in purine catabolism may have clinical relevance in schizophrenia pathology.",
author = "Yao, {Jeffrey K.} and Ruth Condray and Dougherty, {George G.} and Keshavan, {Matcheri S.} and Montrose, {Debra M.} and Matson, {Wayne R.} and McEvoy, {Joseph Patrick} and Rima Kaddurah-Daouk and Reddy, {Ravinder D.}",
year = "2012",
month = "8",
day = "14",
doi = "10.1371/journal.pone.0042165",
language = "English (US)",
volume = "7",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "8",

}

TY - JOUR

T1 - Associations between purine metabolites and clinical symptoms in schizophrenia

AU - Yao, Jeffrey K.

AU - Condray, Ruth

AU - Dougherty, George G.

AU - Keshavan, Matcheri S.

AU - Montrose, Debra M.

AU - Matson, Wayne R.

AU - McEvoy, Joseph Patrick

AU - Kaddurah-Daouk, Rima

AU - Reddy, Ravinder D.

PY - 2012/8/14

Y1 - 2012/8/14

N2 - Background: The antioxidant defense system, which is known to be dysregulated in schizophrenia, is closely linked to the dynamics of purine pathway. Thus, alterations in the homeostatic balance in the purine pathway may be involved in the pathophysiology of schizophrenia. Methodology/Principal Findings: Breakdown products in purine pathway were measured using high-pressure liquid chromatography coupled with a coulometric multi-electrode array system for 25 first-episode neuroleptic-naïve patients with schizophrenia at baseline and at 4-weeks following initiation of treatment with antipsychotic medication. Associations between these metabolites and clinical and neurological symptoms were examined at both time points. The ratio of uric acid and guanine measured at baseline predicted clinical improvement following four weeks of treatment with antipsychotic medication. Baseline levels of purine metabolites also predicted clinical and neurological symtpoms recorded at baseline; level of guanosine was associated with degree of clinical thought disturbance, and the ratio of xanthosine to guanosine at baseline predicted degree of impairment in the repetition and sequencing of actions. Conclusions/Significance: Findings suggest an association between optimal levels of purine byproducts and dynamics in clinical symptoms and adjustment, as well as in the integrity of sensory and motor processing. Taken together, alterations in purine catabolism may have clinical relevance in schizophrenia pathology.

AB - Background: The antioxidant defense system, which is known to be dysregulated in schizophrenia, is closely linked to the dynamics of purine pathway. Thus, alterations in the homeostatic balance in the purine pathway may be involved in the pathophysiology of schizophrenia. Methodology/Principal Findings: Breakdown products in purine pathway were measured using high-pressure liquid chromatography coupled with a coulometric multi-electrode array system for 25 first-episode neuroleptic-naïve patients with schizophrenia at baseline and at 4-weeks following initiation of treatment with antipsychotic medication. Associations between these metabolites and clinical and neurological symptoms were examined at both time points. The ratio of uric acid and guanine measured at baseline predicted clinical improvement following four weeks of treatment with antipsychotic medication. Baseline levels of purine metabolites also predicted clinical and neurological symtpoms recorded at baseline; level of guanosine was associated with degree of clinical thought disturbance, and the ratio of xanthosine to guanosine at baseline predicted degree of impairment in the repetition and sequencing of actions. Conclusions/Significance: Findings suggest an association between optimal levels of purine byproducts and dynamics in clinical symptoms and adjustment, as well as in the integrity of sensory and motor processing. Taken together, alterations in purine catabolism may have clinical relevance in schizophrenia pathology.

UR - http://www.scopus.com/inward/record.url?scp=84865053122&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865053122&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0042165

DO - 10.1371/journal.pone.0042165

M3 - Article

VL - 7

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 8

M1 - e42165

ER -